Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP

/PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Dobutamine Injection, USP, in a 250mg/20mL vial in...

Related Keywords

Portugal ,United States ,Terrugem ,Lisboa ,Canada ,United Kingdom ,London ,City Of ,Dubai ,Dubayy ,United Arab Emirates ,Steve Weiss ,Susan Ringdal ,David Belian ,Us Communications ,Regional Poison Control Center ,Hikma Pharmaceuticals United States Inc ,Public Affairs ,Hikma Pharmaceuticals ,Prnewswire Hikma Pharmaceuticals ,Global Affairs ,Dobutamine Injection ,Riad Mishlawi ,Strategic Planning ,Middle East ,North Africa ,Safety Information ,Heart Rate ,Blood Pressure ,Following Acute Myocardial Infarction ,Ventricular Ectopic Activity ,Intravenous Infusion ,Uncommon Effects ,Teratogenic Effects ,Sodium Bicarbonate Injection ,Dextrose Injection ,Sodium Chloride Injection ,Lactated Ringer ,Sodium Lactate ,Regional Poison Control ,Physician Desk Reference ,Package Insert ,Hikma Pharmaceuticals United States ,Hikma Pharmaceuticals Usa Inc ,